This site uses cookies to improve your experience and to provide services and advertising. By continuing to browse, you agree to the use of cookies described in our Cookies Policy. You may change your settings at any time but this may impact on the functionality of the site. To learn more see our Cookies Policy.
OK
Dublin: 16 °C Saturday 25 May, 2019
Advertisement

Pharmaceutical firm announces €44m investment in Waterford plant

The biotechnology campus produces products for patients living with rare genetic diseases.

Image: Pharmaceutical factory image via Shutterstock

PHARMACEUTICAL COMPANY SANOFI announced today that it will invest €44 million in the Genzyme biotechnology campus in Co Waterford.

More than 500 people are employed at Genzyme Waterford, which produces products for patients living with rare genetic diseases, kidney disease and cholesterol management requirements that are shipped to more than 70 countries around the world.

The investment will increase the site’s range of products by adding the filling of Sanofi’s insulin glargine product which is the number one insulin brand worldwide.

Sanofi acquired Genzyme almost two years ago and the company said today it has been “continually impressed with the record of achievement” at the Waterford site.

Visiting the site today, Minister for Jobs, Enterprise and Innovation, Richard Bruton said this investment, which comes on top of a €150m investment little more than a year ago, will “ensure that this facility can produce the company’s latest product and provides an indication of the Waterford site’s strategic value”.

Read: 500 new jobs announced for Dublin and Galway>

  • Share on Facebook
  • Email this article
  •  

Read next:

COMMENTS (29)